James E. Niedel

Current Institution
New Leaf Ventures
Managing Director

Scholar: 1981

Awarded Institution
Duke University

Research Interests

James Niedel focuses on New Leaf Partner's biopharmaceuticals efforts. He was one of the founders of New Leaf in 2005, having moved with the healthcare team from Sprout, where he had been a venture partner since 2002. Sprout Group is one of the oldest and largest institutional venture capital firms focused on emerging technology companies. Since its founding in 1969, Sprout Group has financed more than 350 companies and has raised nearly $3.0 billion in committed capital from leading institutional investors and individuals active in the technology industry. In November 2000, Sprout Group closed Sprout IX, a fund totaling $1.1 billion. Sprout Group's investment focus is in healthcare technology and communications software.

Prior to his joining Sprout Group, Dr. Niedel was Chief Science and Technology Officer for GlaxoSmithKline and from 1995 to 2001 he was a member of the board of directors of Glaxo Wellcome plc with responsibility for Global Research and Development, Information Technology and Product Strategy. From 1988 to 1995 he was VP Research and SVP R&D for the US subsidiary of Glaxo. Before joining the pharmaceutical industry, he was Professor of Medicine and Chief of the division of Clinical Pharmacology at Duke Medical School, where he had completed an Internal Medicine residency and a Hematology-Oncology fellowship. He received M.D. and Ph.D. (Biochemistry) degrees from the University of Miami and is a Fellow of the Royal College of Physicians (London).